Plant Stem Cell Market 2026 Growth Trends by Manufacturers, Regions, Type and Application, Forecast – Latest Herald

The global Plant Stem Cell Market research report thoroughly explains each and every aspect related to the Plant Stem Cell Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. The growth trend forecasted on account of thorough examination offers in-depth information regarding the global Plant Stem Cell Market. A pathway of development is offered by the market to the several connected networks of businesses under it, which include different firms, industries, organizations, vendors, distributors, and local manufacturers too. All the key Plant Stem Cell Market players compete with each other by offering better products and services at a reasonable price in order to grab significant share at the regional and global level market.

Plant stem cells are undifferentiated cells within the meristems of plants.Plantstem cellsserve as the origin of plant vitality as they maintain themselves and provide a steady supply ofprecursor cellsto form various tissues and organs in plants. Plant stem cells are characterized by two distinctive properties namely its ability to create differentiated celltypes and to self-renew such that the number of stem cells remain stable. The plant stem cell market focuses on this ability of plant cells and thus, processed extracts from the buds, roots and shoots are in high demand and are widely used for topical uses.ription

Get a Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/98

The report incorporates an estimated impact of strict standards and regulations set by the government over the market in the upcoming years. The market report also comprises exhaustive research done using several analytical tools such as SWOT analysis to identify the market growth pattern.

Top Manufacturers in GlobalPlant Stem CellMarket Includes:Oriflame Holding AG, MyChelle Dermaceuticals, LLC, Natura Therapeutics Inc, Aidan Products LLC, Mibelle Biochemistry, Phyto Science SDN BHD, and Renature Skin Care Inc.

Regions & Countries Mentioned In The Plant Stem Cell Market Report:

North America ( United States)

Europe ( Germany, France, UK)

Asia-Pacific ( China, Japan, India)

Latin America ( Brazil)

The Middle East & Africa

Key Highlights of the Table of Contents:

Plant Stem Cell Market Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global market, years considered, and study objectives. Furthermore, it tuches the segmentation study provided in the report on the basis of the type of product and applications.

Plant Stem Cell Market Executive Summary: This section emphasizes on the key studies, market growth rate,Competitive landscape, market drivers, trends, and issues.

Plant Stem Cell Market Production by Region: The report provides information related to import and export, production, revenue, and key players of all regional markets studied are covered in this section.

Plant Stem Cell Market Profile of Manufacturers: Analysis of each market player profiled is detailed in this section. This also provides SWOT analysis, products, production, value, capacity, and other vital factors of the individual player.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/98

Table of Contents

Report Overview:It includes the Plant Stem Cell market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Plant Stem Cell market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Plant Stem Cell market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Plant Stem Cell market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Access insightful study with over 100+ pages, list of tables & figures, profiling 10+ companies https://www.coherentmarketinsights.com/insight/request-pdf/98

About CMI:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Coherent Market Insights 1001 4th Ave,#3200 Seattle, WA 98154,U.SPhone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Link:
Plant Stem Cell Market 2026 Growth Trends by Manufacturers, Regions, Type and Application, Forecast - Latest Herald

Mary Wilson to receive UB’s Norton Medal – UB News Center

Release Date: May 5, 2020

BUFFALO, N.Y. Mary Wilson, wife of the late Buffalo Bills owner Ralph Wilson and a strong advocate of Western New York for the past 29 years, will be awarded the Chancellor Charles P. Norton Medal, UBs highest honor.

Jean Wactawski-Wende, SUNY Distinguished Professor in the Department of Epidemiology and Environmental Health and dean of the School of Public Health and Health Professions, and an internationally recognized researcher on womens health issues, will receive the UB Presidents Medal in recognition of extraordinary service to the university.

In addition, SUNY honorary doctorates are being presented to UB alumna Donnica L. Moore, president of the Sapphire Womens Health Group, and Richard A. Schatz, research director of cardiovascular interventions at the Scripps Heart, Lung and Vascular Center.

Wactawski-Wende will receive the Presidents Medal during the School of Public Health and Health Professions virtual commencement ceremony on May 16; the other award recipients will receive their honors at a later date.

Chancellor Charles P. Norton Medal

The Chancellor Charles P. Norton Medal is presented annually in public recognition of a person who has, in Nortons words, performed some great thing which is identified with Buffalo a great civic or political act, a great book, a great work of art, a great scientific achievement or any other thing which, in itself, is truly great and ennobling, and which dignifies the performer and Buffalo in the eyes of the world.

Announcing this years Norton Medal recipient, Jeremy M. Jacobs, chair of the UB Council, said that Mary Wilson a life trustee of the Ralph C. Wilson, Jr. Foundation richly deserves the honor for her longstanding commitment to the region.

This year, we were absolutely unanimous in our decision to honor Mary Wilson, he said. In her leadership of the Wilson Foundation, Mary is making an enduring and unprecedented impact on Buffalo and all of Western New York, which will be felt for many generations to come. Her dedication and work align perfectly with the spirit of the Norton Medal.

Wilson has been devoted to Western New York since she first arrived in the area for the Bills home opener in 1990.

She has spent many years developing her Western New York Girls in Sports program, which biannually brings more than 200 9- to 12-year-old girls together to take part in various sports taught by young athletes from local universities and sports clubs.

The program, now ensured to run in perpetuity, is organized by the United Way of Buffalo and Erie County through an endowment from the Ralph C. Wilson, Jr. Foundation.

She has also supported organizations benefiting communities in Buffalo, Erie County and Southeast Michigan, among them Hospice of Western New York, WNY Womens Foundation, Food Bank of Western New York, Albright-Knox Art Gallery, Girl Scouts of Western New York, the SPCA serving Erie County, the Buffalo Philharmonic Orchestra, the Alzheimers Association Greater Michigan Chapter, The Helm (formerly Services for Older Citizens), the Detroit Symphony Orchestra, the Detroit Historical Society and the Detroit Institute of Arts, to name a few.

UB Presidents Medal

The UB Presidents Medal, first presented in 1990, recognizes outstanding scholarly or artistic achievements, humanitarian acts, contributions of time or treasure, exemplary leadership or any other major contribution to the development of the University at Buffalo and the quality of life in the UB community.

President Satish K. Tripathi described recipient Jean Wactawski-Wende as a world-renowned epidemiologist who has brought great prominence to UB through her scholarly pursuits and academic excellence in the area of womens health.

A dedicated member of our university community for more than 30 years, Dr. Wactawski-Wende has made seminal contributions that have significantly impacted health care practice and disease prevention for women in the U.S. and around the world, he said.

Thanks to her tremendous leadership, she has further elevated the reputation of UB. Our university community, along with the many communities we serve, have been profoundly enriched by Dr. Wactawski-Wendes scholarship, teaching and service, and it is an honor to present the Presidents Medal to such a truly deserving recipient.

Of particular note is Wactawski-Wendes leadership role in the Womens Health Initiative (WHI), the largest longitudinal study of womens health in the United States. In 1993, she was part of the team that spearheaded UBs successful bid to become one of the federally funded studys 16 original vanguard clinical centers. Since the inception of the WHI, UB has received more than $30 million in funding from the National Institutes of Health to investigate health issues impacting postmenopausal women.

Among the WHIs major discoveries was the groundbreaking finding that intake of combined estrogen plus progestin was associated with an increased risk of heart disease, stroke and invasive breast cancer. That research, on which Wactawski-Wende served as a co-principal investigator, changed the use of hormone therapy in older women worldwide, potentially saving countless lives.

Through UBs current $6.2 million award extension of the WHI, she has overseen the continuation of research into many diseases associated with aging, such as cardiovascular disease, cancer, osteoporosis, stroke and dementia. She is also administering new studies that focus on frailty and predictors of healthy aging.

For those of us who know and have worked closely with Dr. Wactawski-Wende, we readily recognize the magnitude and excellence of her contributions to academic medicine, said Michael E. Cain, vice president for health sciences and dean of the Jacobs School of Medicine and Biomedical Sciences at UB.

She is an eminent and distinguished scholar and leader whose work, professional service, and stature in her discipline and research field are outstanding and continue to grow.

SUNY Honorary Doctorates

An internationally recognized womens health expert and advocate, Donnica L. Moore is president of Sapphire Womens Health Group, a multimedia firm that educates women about the benefits of a healthy lifestyle.

A pioneering physician, Moore utilizes public speaking and multiple media platforms including her own website and podcast to share impactful health information in laypersons terms.

She will receive a SUNY Honorary Doctorate in Science.

Dr. Moores significant accomplishments associated with women's health set an inspiring example for our university community and reflect the values of both UB and the SUNY system, Tripathi said.

Breaking barriers to educate women about an array of health-related topics, she has demonstrated a sustained and dedicated commitment to the well-being of women around the globe. One of UBs most distinguished alumni, Dr. Moore in utilizing accessible platforms to create broad access to sound, peer-reviewed medical information is enhancing lives in communities near and far.

Moore is a 1986 alumna of the Jacobs School of Medicine and Biomedical Sciences at UB, and underwent residency training in obstetrics and gynecology at Temple University, followed by a year of family medicine training at Memorial Hospital of Burlington, New Jersey.

She has appeared more than 800 times on such programs as The Oprah Winfrey Show, The Anderson Cooper Show and Good Morning America.

Richard A. Schatz is co-creator of the first coronary stent approved by the Food and Drug Administration for restenosis.

Known as the Palmaz-Schatz stent, this life-saving device has been used to treat coronary artery disease in nearly 100 million patients worldwide since its approval in 1994. It is considered one of the top 10 medical device patents of the past 50 years.

He will receive a SUNY Honorary Doctorate in Science.

Dr. Schatz is widely known as the father of modern interventional cardiology for good reason, Tripathi said. Every day, his groundbreaking work is realized in operating rooms across the country and beyond. The stent he co-created spurred a revolution in the treatment of coronary artery disease and, 30 years later, it has had an immeasurable impact on health care.

By contributing to society through his biomedical innovations and inventions, Dr. Schatz has improved the lives of tens of millions of people while embodying the ideals of our university community and our university system.

A New York native, Schatz is the research director of cardiovascular interventions at the Scripps Clinic and director of gene and stem cell therapy. He is an elected fellow of the American College of Cardiology. In 2019, he received the Fritz J. And Dolores H. Russ Prize, which recognizes biomedical engineering achievements that have significantly improved the human condition. He is also the recipient of the Barton Haynes Lifetime Scholar Award from Duke University Medical Center.

Schatz attended UB in the early 1970s before gaining early admission to Duke Medical School, then completed his cardiology training at Brooke Army Medical Center.

Throughout his career, he has maintained a strong affinity for UB, crediting the universitys faculty and curriculum for inspiring him to pursue a career in medicine.

Media Contact Information

Read this article:
Mary Wilson to receive UB's Norton Medal - UB News Center

GLOBAL STEM CELL MANUFACTURING MARKET 2020 FUTURE GROWTH WITH TOP PLAYERS THERMO FISHER SCIENTIFIC. MERCK GROUP, BECTON, DICKINSON AND COMPANY….

Stem Cell Manufacturing Marketis expected to reach USD 16.51 Billion by 2025, from USD 10.28 Billion in 2017 growing at a CAGR of 6.1% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Get Sample Report PDF | @http://databridgemarketresearch.com/request-a-sample/?dbmr=global-artificial-intelligence-market

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Major Market competitors/players: Global Stem Cell Manufacturing Market

Some of the major players operating in the stem cell manufacturing market are Thermo Fisher Scientific. Merck Group, Becton, Dickinson and Company. Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis Inc, Osiris Therapeutics, Osiris Therapeutics, Vericel Corporation, AbbVie, American CryoStem, AM-Pharma, Anterogen.Co.,Ltd, Astellas Pharma, Bristol-Myers Squibb, Apceth Biopharma, Cellular Dynamics International, Rheacell, Takeda Pharmaceutical, Teva Pharmaceutical Industries Ltd. ViaCyte, VistaGen Therapeutics Inc, Translational Biosciences, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, among others.

Global Stem Cell manufacturing Market,By Application (Research Applicationsand Clinical Applicationsand Cell and Tissue Banking), By Product (Stem Cell Line, Instruments, Culture Media and Consumables), By End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Table of Contents:

Highlights of the Study

Inquire about this report from our experts @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market

Major Market Drivers:

Report Scope

Our purpose is to serve you, the most customised in-depth Market access data. Our plethora of titles, made us one of the most searched market research library across the globe. We work with the most esteemed Publishers around the globe who caters vast industries. We are quick and fragile, when it comes to your various queries, and we ensure our team cater your needs to the best of our abilities, we promise to stay by your side for both pre and post sales servicing, as we believe in long everlasting symbiotic relationship.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:[emailprotected]

Go here to read the rest:
GLOBAL STEM CELL MANUFACTURING MARKET 2020 FUTURE GROWTH WITH TOP PLAYERS THERMO FISHER SCIENTIFIC. MERCK GROUP, BECTON, DICKINSON AND COMPANY....

Stem Cell and Primary Cell Culture Medium Market Analysis, Size, Share and Forecast 2020-2026 Market Research Report | Merck, STEMCELL Technologies,…

The global Stem Cell and Primary Cell Culture Medium market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Researchs latest publication, titled global Stem Cell and Primary Cell Culture Medium market, offers an insightful take on the drivers and restraints present in the market. It assesses the historical data pertaining to the global Stem Cell and Primary Cell Culture Medium market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market. A team subject-matter experts have provided the readers a qualitative and quantitative data about the market and the various elements associated with it.

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Stem Cell and Primary Cell Culture Medium Market which would mention How the Covid-19 is Affecting the Stem Cell and Primary Cell Culture Medium Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Stem Cell and Primary Cell Culture Medium Players to Combat Covid-19 Impact.

Get the Sample of this Report with Detail TOC and List of [emailprotected]https://www.qyresearch.com/sample-form/form/1679378/covid-19-impact-on-global-stem-cell-and-primary-cell-culture-medium-market

The research report covers the trends that are currently implemented by the major manufacturers in the Stem Cell and Primary Cell Culture Medium market including adoption of new technology, government investments on R&D, shifting in perspective towards sustainability, and others. Additionally, the researchers have also provided the figures necessary to understand the manufacturer and its contribution to both regional and global market:

Merck, STEMCELL Technologies, Irvinesci, Cell Applications, Inc, Biological Industries, Miltenyi Biotec, Swiss Medica Clinic, Promocell, Creative Biolabs, Lifeline Cell Technology, ScienCell Research Laboratories, Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Stem Cell and Primary Cell Culture Medium market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

Market Segments Covered:

Segmentation by Product Types:Liquid MediaPowder Media

Segmentation by Applications:Biopharmaceutical ManufacturingTissue Engineering & Regenerative MedicineGene TherapyOther

Regions Covered in the Global Stem Cell and Primary Cell Culture Medium Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report Accurate market size and CAGR forecasts for the period 2019-2025 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Stem Cell and Primary Cell Culture Medium market Exhaustive research on innovation and other trends of the global Stem Cell and Primary Cell Culture Medium market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report segments the global Stem Cell and Primary Cell Culture Medium market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritties of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also address political scenarios that are expected to impact the market in both small and big ways.The report on the global Stem Cell and Primary Cell Culture Medium market examines changing regulatory scenario to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Ask for Customized Report as per Your [emailprotected]https://www.qyresearch.com/customize-request/form/1679378/covid-19-impact-on-global-stem-cell-and-primary-cell-culture-medium-market

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Stem Cell and Primary Cell Culture Medium market

Chapter 2: Evaluating the leading manufacturers of the global Stem Cell and Primary Cell Culture Medium market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Stem Cell and Primary Cell Culture Medium market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9 : To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

About Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Go here to see the original:
Stem Cell and Primary Cell Culture Medium Market Analysis, Size, Share and Forecast 2020-2026 Market Research Report | Merck, STEMCELL Technologies,...

Adoption of Human Platelet Lysate Market Through COVID-19 Pandemic to Increase Across Top Countries in the Globe IN the Coming Years – Cole of Duty

Rising funding for research & development activities, increasing number of research centers, and growing partnerships between research centers, biotechnology companies, and academic institutes for basic research are the prominent driving factors for the growth of thehuman platelet lysate market.

Also, increasing demand for animal-free serum media is a key catalyzer for the growth of the human platelet lysate market. Human platelet lysates, a growth supplement for in-vitro cell culture, are a suitable alternative to fetal bovine serum, and expected to find application in various therapeutics. The global human platelet lysate market is set to progress at a decent CAGR of around 4% over the period of 2019 to 2029.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/16789

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/16789

Key Takeaways from Human Platelet Lysate Market Study

Manufacturers can focus on developing countries such as India that offer significant gains in terms of revenue, through the sale of human platelet lysates at an economical cost,says a PMR analyst.

Increase in Life Science Research Funding

Various government, private, and commercial organizations are focused on increasing research & development activities for continuous innovation in the field of life sciences. These organizations provide funds for ongoing research projects and pipeline products. In 2013, around 59% of total research & development expenditure in the U.S. was from federal funding agencies. In 2016, the National Institute of Health reported investments of nearly US$ 1.4 Bn toward stem cell research in the field of cell biology and electrical engineering.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/16789

Want More Insights?

A new report by Persistence Market Research provides unparalleled insights on the evolution of the human platelet lysate market during 2014-2018, and presents demand projections for 2019-2029, on the basis of product type (heparin-free platelet lysates and human platelet lysates with heparin), application (research use and clinical use), and end user (academic and research institutes, biopharmaceutical companies, and other applications), across various prominent regions (North America, Latin America, Europe, East Asia, South Asia. Oceania, and MEA).

Read this article:
Adoption of Human Platelet Lysate Market Through COVID-19 Pandemic to Increase Across Top Countries in the Globe IN the Coming Years - Cole of Duty

Stem Cell Treatment for COVID-19; Doctors Divided on Its Scope – The Quint

A team of doctors and researchers at the Abu Dhabi Stem Cell Center (ADSCC) administered the treatment in the UAE to 73 COVID-19 patients, who were all successfully treated and cured, without any immediate side effects, according to a statement by the United Arab Emirates (UAE) health ministry from 1 May.

The process involved a minimally invasive method where the patients stem cells are extracted, activated and turned into fine mist to be inhaled into the lungs. This was done in addition to the conventional treatment and is expected to work by supporting the established protocol of management of symptoms.

The ministry said in the statement, It is hypothesised to have its therapeutic effect by regenerating lung cells and modulating the immune response to keep it from overreacting to the COVID-19 infection and causing further damage to healthy cells.

The treatment has successfully undergone the initial phase of clinical trials, demonstrating its safety, and further trials for its efficiency are ongoing; expected to be completed in a couple of weeks.

Dr Fatima al-Kaabi, head of haematology and oncology at the Sheikh Khalifa Medical City in the UAE, told CNBC, Its very early to say at this stage. If all went well, this could reach the market in three months, she added.

Going further back, a pilot study in China on seven COVID-19 patients found that intravenous infusions of donor mesenchymal stem cells (MSC) - multipotent stem cells - improved patient outcomes and helped all of them recover. An Israeli pharmaceutical company, Pluristem Therapeutics, also tested stem cells in seven critical hospitalized patients and found positive results.

Additionally, the US Food and Drug Administration (FDA) approved MSC use in extremely sick COVID-19 patients under expanded access compassionate use on 5 April according to a report in The Scientist, even though the experts seemed divided on the logic on which the investigative treatment may have worked.

A hospital in New York tried the therapy as an experiment on 12 patients, 10 of whom were able to come off ventilators, reports CBS news. The Australian regenerative medicine company Mesoblast has also announced a 300-person trial for its stem cell therapy remestemcel-L (which was used in the New York trial) to determine whether it will work on patients suffering with severe lung inflammation.

Currently, there are over 20 active stem cell trials for COVID-19, most focusing on the use of MSCs.

View original post here:
Stem Cell Treatment for COVID-19; Doctors Divided on Its Scope - The Quint

Mike Tyson, 53, reveals he had stem cell research therapy and hadnt hit bags for 15 YEARS before returning t – The Sun

MIKE TYSON revealed how he has started training again having not thrown a punch for a staggering 15 years - and is being aided by stem-cell research therapy.

The Baddest Man on the Planet, who hung up his gloves in 2005 following defeat by Kevin McBride, wouldn't elaborate on why he was having the treatment but added that it was 'really wild what scientists can do'.

4

Tyson was having an Instagram chat with basketball legend Shaquille O'Neal when he revealed that he had been training for the previous three days after 15 years away - and his new health regime.

Iron Mike said: "You know what I had done? I had stem-cell research therapy.

"I feel like a different person but I can't comprehend why I feel this way. It's really wild what scientists can do."

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition that usually takes the form of a bone marrow transplantation.

He did not reveal what the exact condition was that was being treated.

Despite letting the gloves gather dust in the corner, it didn't take long for Iron Mike to show off that lethal punching power.

4

The 53-year-old delighted fans in lockdown by uploading a viral video of him laying into a punchbag with his trademark speed and power.

Tyson's weight ballooned after retiring following battles with drug addiction and depression.

But he has since partnered with a new trainer, MMA coach Rafael Cordeiro, to kick-start his training after sensationally revealing his 15-year break.

During their chat, basketball legend O'Neal revealed how he ached for three days after playing with his sons.

Tyson responded: "That's just because you haven't done it for a while.

WHAT IS STEM CELL TREATMENT USED FOR?

Stem cell transplants are carried out when bone marrow is damaged or isnt able to produce healthy blood cells.

It can also be used to replace damaged blood cells as the result of intensive cancer treatment.

Here are conditions that stem cell transplants can be used to treat:

"If you continue to do it consistently you'll be back to normal.

"It's just like me, I haven't boxed or hit the bag for 15 years - it has been three days so far and I feel incredible."

Tyson, who has a 50-6 record, is reportedly gearing up for a sensational return amid plans to compete in exhibition bouts for charity later this year.

He told rapper T.I. last month: "I've been hitting the mitts for the last week.

"That's been tough, my body is really jacked up and really sore from hitting the mitts.

MIKE DROPTyson shows off body transformation with 53-year-old preparing for boxing return

HOLY MOLYHolyfield hints at comeback aged 57 after Tyson announces plans to return to ring

NO GLOVE LOSTJoshua tells Froch to 'shut up, blud' as war of words continues

WHATSAPP-ENING?Joshua sent Froch four now-deleted messages after his P4P rant

IT WILL ALL END IN PIERSPiers Morgan and Eddie Hearn in Twitter spat over coronavirus

SHOWDOWNHall vs Bjornsson: How giants compare as Beast threatens deadlift record holder

NEED FOR SPEEDMike Tyson, 53, shows off speed as heavyweight legend gears up for return

HOME FIGHTERDubois enjoys lockdown sparring with siblings after buying family pad

DO OR TYMike Tyson's trainer 'saw life flash before his eyes' in scary training clip

"I've been working out, I've been trying to get in the ring, I think I'm going to box some exhibitions and get in shape.

"I want to go to the gym and get in shape to be able to box three or four-round exhibitions for some charities and stuff.

"Some charity exhibitions, make some money, help some homeless and drug-affected motherf****er like me."

4

4

Here is the original post:
Mike Tyson, 53, reveals he had stem cell research therapy and hadnt hit bags for 15 YEARS before returning t - The Sun

Century Therapeutics Announces Formation of Scientific Advisory Board – Business Wire

PHILADELPHIA--(BUSINESS WIRE)--Century Therapeutics, developer of induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies for cancer, today announced the formation of its Scientific Advisory Board (SAB) to include several renowned experts in the fields of developmental and stem cell biology, genetics, and immuno-oncology. The SAB will work closely with Century as it develops off-the-shelf iPSC-derived adaptive and innate immune effector cell therapies to treat hematologic and solid malignancies.

We are privileged to welcome these distinguished scientists as inaugural members of our Scientific Advisory Board, said Lalo Flores, PhD, CEO at Century Therapeutics. Their expertise in disciplines central to the control of cellular differentiation and lymphocyte function as applied to the field of immuno-oncology will bring external scientific and clinical-translational perspectives to help guide Century in the development and expansion of our allogeneic cell therapy technology.

Centurys President of R&D, Hy Levitsky, M.D., said, Were looking forward to leveraging the deep scientific expertise and insights this elite group brings to bear on the design and development of both iPSC-derived CAR-NK and CAR-T cell products.

Centurys Scientific Advisory Board members are:

In addition to the creation of the science-focused SAB, Century will also convene a disease-focused clinical advisory board to be chaired by Dr. Marcela Maus who is a scientific co-founder of Century Therapeutics.

About Century Therapeutics

Century Therapeutics is harnessing the power of stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. Our genetically engineered, universal iPSC-derived immune effector cell products (NK, T, DC and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care. Century was launched in 2019 by founding investor Versant Ventures in partnership with Fujifilm and Leaps by Bayer. For more information, please visit http://www.centurytx.com.

Visit link:
Century Therapeutics Announces Formation of Scientific Advisory Board - Business Wire

Liberal MP Jim Carr to receive stem-cell transplant to treat blood cancer – The Globe and Mail

Jim Carr speaks to the Calgary Chamber of Commerce, on Jan. 14, 2020.

Jeff McIntosh/The Canadian Press

Liberal MP and former cabinet minister Jim Carr is returning to hospital for a stem-cell transplant, a treatment that had been twice delayed due to the COVID-19 pandemic.

The Winnipeg MP shared the news on social media Tuesday morning, saying that he and his family remain grateful for all the support they have received since his cancer was discovered last fall.

He said he expects to be recovering in hospital for the next few weeks.

Story continues below advertisement

The past few months have been a challenging and unprecedented time for everyone but I know that we will get through this and emerge stronger than ever, he wrote in a message posted to Twitter.

Carr had been diagnosed with multiple myeloma after experiencing flu-like symptoms during the 2019 federal election campaign.

In his own social-media post Tuesday, Carrs son Ben said life has not been the same for the family since the diagnosis, but the fact his father had been campaigning with failing kidneys and cancer running through his blood spoke to his character.

Anyone who was with us during the campaign can tell you just how tough he is, he wrote.

Carr had headed into that campaign as the Liberals international trade diversification minister, and was one of only a handful of Liberals re-elected in the Prairie provinces in the October vote.

He stepped back from cabinet following his diagnosis to undergo treatment, though Prime Minister Justin Trudeau appointed him as a special representative for the region.

Less than a year ago he was Canadas trade minister, travelling around the world to make the country a better place, Ben Carr wrote.

Story continues below advertisement

Lately, hes been resigned to his living room. A pretty tough reality to confront, no question.

His son said the stem cell transplant had been cancelled twice because of COVID-19, and the pandemic is also forcing the family apart during an exceptionally difficult time.

For me personally, one of the worst parts of whats been happening is the loss of connection with my dad. Although we speak every day by video call, it isnt the same. No hugs, no shared meals, no sitting beside each other watching sports, he wrote.

He said normally hed go visit his father during his recovery, but this time wont be allowed in the hospital.

I love you, dad. See you on the other side.

Last fall, Carrs colleague Dominic Leblanc also underwent a stem-cell transplant, this one to treat non-Hodgkins lymphoma.

Story continues below advertisement

The New Brunswick MP had been diagnosed with that cancer in the spring of 2019.

Know what is happening in the halls of power with the days top political headlines and commentary as selected by Globe editors (subscribers only). Sign up today.

See the rest here:
Liberal MP Jim Carr to receive stem-cell transplant to treat blood cancer - The Globe and Mail

BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure -…

SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced data from a recent animal study performed by the Company that demonstrate meaningful improvements in heart function for subjects treated with its allogenic (from another donor, or off the shelf) neurokinin 1 receptor positive mesenchymal stem cell (NK1R+ MSC) program for heart failure, known as CardiALLO. In addition, the Company is planning further exploration and discussion with the U.S. Food and Drug Administration (FDA) on the use of its allogenic cells for COVID-19 related Acute Respiratory Distress Syndrome (ARDS).

In the 26 animals treated with both low dose and high dose NK1R+ MSC, echocardiographic measures of cardiac ejection fraction, fractional shortening and cardiac outflow were meaningfully improved, with all three measures being statistically significant for both dosage levels over control animals.

The CardiALLO cell therapy is being developed initially to treat heart failure patients whose cells do not qualify for its lead autologous cell therapy, CardiAMP (BCDA-01).

BioCardia Chief Scientific Officer Ian McNiece, PhD, said, In light of these positive data on our allogenic NK1R+ MSC therapy, we expect to meet our internal timeline to complete our submission to the FDA for our first indication for CardiALLO, and potentially receive IND acceptance by the end of the second quarter. The MSCs that were studied are subtypes of MSC that we have delivered previously in our co-sponsored trials, which we believe have enhanced potency over MSC generated from unselected bone marrow cells. We look forward to seeing additional data from this animal study that are currently being analyzed, including histology and pathology of the heart and lungs.

COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) Exploration

The Company also intends to submit an IND for the use of its NK1R+ MSC delivered via intravenous (IV) infusion for Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19.

Based on preliminary clinical reports on COVID-19, respiratory failure complicated by ARDs is the leading cause of death for COVID-19 patients.1 ARDS is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs.

The anti-inflammatory effects of MSC have been well-documented and MSC have been shown to reduce inflammation and injury in models of lung disease.2 The specific MSCs used in BioCardias allogenic cell therapy are expanded from cells selected for the presence of the NK1 receptor, which is known to bind to substance P, an important neuropeptide associated with inflammation throughout the body and a primary mediator of inflammation in the airways.3,4

Our NK1R+ allogenic MSC may have more potential than other MSC approaches being advanced today due to their interaction with Substance P, said BioCardia CEO Peter Altman, PhD. This COVID-19 related work will be the Companys first clinical investigation outside of the cardiac space and our first exploring therapy for the lung. A recent patent publication (US 2020/0101113 A1) shows that BioCardia has long intended for these remarkable reparative cells to be targeted for respiratory disorders, in addition to cardiovascular disease. Addressing inflammation in the lungs is an important contribution we may be able to make using our NK1R+ allogenic MSC therapy.

The Companys allogenic cells are expected to be manufactured at BioCardias clinical stage cell manufacturing facility in San Carlos, California.

About BioCardiaBioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the Companys biotherapeutic product candidates in clinical development. The Company's approved products include the Helix transendocardial delivery system and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix System and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

Forward Looking Statements This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the development of NK1R+ cells for the treatment of heart failure and ARDS secondary to COVID-19, potential FDA IND acceptances, and potential FDA filings, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardias Form 10-K filed with the Securities and Exchange Commission on April 9, 2020, under the caption titled Risk Factors. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact: Michelle McAdam, Chronic Communications, Inc.michelle@chronic-comm.com(310) 902-1274

Investor Contact: David McClung, Chief Financial Officerinvestors@BioCardia.com(650) 226-0120

See the original post here:
BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure -...